Dose-escalation Study of BIBH 1 in Patients With Non-small Cell Lung Cancer Scheduled for Surgical Resection
NCT02199886
·
clinicaltrials.gov ↗
PHASE1
Phase
TERMINATED
Status
6
Enrollment
INDUSTRY
Sponsor class
Conditions
Lung Neoplasms
Interventions
DRUG:
BIBH 1
Sponsor
Boehringer Ingelheim